Changeflow GovPing Pharma & Drug Safety Signum Biosciences Chia Seed Extract Patent Gra...
Routine Rule Added Final

Signum Biosciences Chia Seed Extract Patent Granted

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted patent US12599642B2 to Signum Biosciences Inc on April 14, 2026. The patent covers compositions derived from Salvia hispanica (chia) seeds and methods of preparation and administration. The 18 claims span dermatological applications including skin care and sunscreen formulations. Third parties face no compliance obligations from this patent grant.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO granted patent US12599642B2 for compositions derived from Salvia hispanica (chia) seeds and methods of preparing and administering chia seed extracts. The patent names 8 inventors and includes 18 claims covering dermatological applications including skin care and sun protection products.

For manufacturers and researchers in the pharmaceutical and food sectors, this patent establishes IP rights that may restrict development of competing chia seed extract products for similar applications until the patent's expiration. Parties should conduct freedom-to-operate analyses before commercializing related products.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Compositions derived from Salvia hispanica seeds

Grant US12599642B2 Kind: B2 Apr 14, 2026

Assignee

SIGNUM BIOSCIENCES INC

Inventors

Jose Fernandez, Eddie Perez, Kristen Huber, Jason Healy, Corey Webb, Karl Rouzard, Mike Voronkov, George Nikonov

Abstract

Methods of preparing a composition from chia seeds are provided. Compositions, including compositions prepared by the presently disclosed methods, and methods regarding selecting chia seeds and administering chia seed extracts are also disclosed.

CPC Classifications

A61K 36/537 A61K 2236/15 A61K 2236/33 A61K 2236/37 A61K 2236/51 A61K 2236/53 A61K 8/9789 A61K 2236/00 A61K 9/0014 A61Q 19/00 A61Q 17/04 A61P 17/00 A61P 17/06 A61P 25/00 A61P 25/28 A61P 31/04

Filing Date

2021-03-04

Application No.

17909387

Claims

18

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599642B2

Who this affects

Applies to
Manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting IP licensing Chia seed extract
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!